BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 3082832)

  • 1. Non-antitumor vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro.
    Inaba M; Nagashima K
    Jpn J Cancer Res; 1986 Feb; 77(2):197-204. PubMed ID: 3082832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
    Tsuruo T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Studies on the mechanism of multidrug resistance].
    Inaba M
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):807-14. PubMed ID: 3471182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
    Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW
    Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics.
    Tsuruo T
    Cancer Treat Rep; 1983 Oct; 67(10):889-94. PubMed ID: 6354436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of resistance to anthracyclines and vinca alkaloids.
    Danø K; Skovsgaard T; Nissen NI; Friche E; Di Marco A
    Prog Clin Biol Res; 1983; 132C():231-46. PubMed ID: 6579564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
    Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
    Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists.
    Kessel D; Wilberding C
    Cancer Res; 1985 Apr; 45(4):1687-91. PubMed ID: 3919944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis of active efflux of vincristine from multidrug-resistant P388 leukemia cells.
    Inaba M; Watanabe T; Sugiyama Y
    Jpn J Cancer Res; 1987 Apr; 78(4):397-404. PubMed ID: 3108219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
    Beck WT; Cirtain MC; Look AT; Ashmun RA
    Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine.
    Sertel S; Fu Y; Zu Y; Rebacz B; Konkimalla B; Plinkert PK; Krämer A; Gertsch J; Efferth T
    Biochem Pharmacol; 2011 Mar; 81(6):723-35. PubMed ID: 21219884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.
    Inaba M; Maruyama E
    Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.
    Inaba M; Kobayashi H; Sakurai Y; Johnson RK
    Cancer Res; 1979 Jun; 39(6 Pt 1):2200-3. PubMed ID: 445418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New compounds with cytotoxic and antitumor effects. Part 6: Monomeric indole alkaloids of vinca minor L. and their effect on P388 cells.
    Sturdíková M; Fuska J; Grossmann E; Votický Z
    Pharmazie; 1986 Apr; 41(4):270-2. PubMed ID: 3725874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Characteristics of anthracycline-resistant strains of P388 leukemia].
    Goncharova SA; Demidova NS; Shiriaeva OA; Shevtsova VN; Konovalova NP
    Eksp Onkol; 1987; 9(4):42-7. PubMed ID: 3678124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
    Johnson RK; Chitnis MP; Embrey WM; Gregory EB
    Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markedly altered membrane transport and intracellular binding of vincristine in multidrug-resistant Chinese hamster cells selected for resistance to vinca alkaloids.
    Sirotnak FM; Yang CH; Mines LS; Oribé E; Biedler JL
    J Cell Physiol; 1986 Feb; 126(2):266-74. PubMed ID: 3944208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
    Lepri E; Menconi E; Barzi AM
    Boll Soc Ital Biol Sper; 1984 Jul; 60(7):1369-75. PubMed ID: 6477749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of multidrug resistance by non-antitumor anthracycline analogs.
    Inaba M; Nagashima K; Sakurai Y; Fukui M; Yanagi Y
    Gan; 1984 Dec; 75(12):1049-52. PubMed ID: 6597118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.
    Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Res; 1981 May; 41(5):1967-72. PubMed ID: 7214365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.